Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 Next >

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

February 23, 2024

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

February 19, 2024

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

February 19, 2024

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer

February 16, 2024

From AstraZeneca

Via Business Wire

AstraZeneca Full year and Q4 2023 Financial Results

February 08, 2024

From AstraZeneca

Via Business Wire

AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development

February 06, 2024

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors

January 29, 2024

From AstraZeneca

Via Business Wire

AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

January 22, 2024

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization

January 19, 2024

From AstraZeneca

Via Business Wire

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

December 26, 2023

From AstraZeneca

Via Business Wire

WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

December 21, 2023

From AstraZeneca

Via Business Wire

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

December 12, 2023

From AstraZeneca

Via Business Wire

AstraZeneca advances scientific leadership in hematology at ASH 2023

November 29, 2023

From AstraZeneca

Via Business Wire

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

November 20, 2023

From AstraZeneca

Via Business Wire

TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer

November 17, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial

November 09, 2023

From AstraZeneca

Via Business Wire

AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity

November 08, 2023

From AstraZeneca

Via Business Wire

Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial

November 03, 2023

From AstraZeneca

Via Business Wire

US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)

October 24, 2023

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

October 23, 2023

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

October 23, 2023

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

October 23, 2023

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial

October 22, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

October 21, 2023

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline

October 21, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone

October 20, 2023

From AstraZeneca

Via Business Wire

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

October 16, 2023

From AstraZeneca

Via Business Wire

AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge

October 12, 2023

From AstraZeneca

Via Business Wire

AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO

October 11, 2023

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

September 22, 2023

From AstraZeneca

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.